TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Effectiveness of CAD EYE system in screening for neoplastic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptoms of organ-specific late effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Signs of organ-specific late effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tests to assess organ-specific late effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Yatchmenoff Client Engagement Scale - Modified
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Recovery Assessment Scale - Revised (RAS-R)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 9-item Internalized Stigma of Mental Illness Inventory (ISMI-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CMR-assessed STEMI severity at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse remodeling at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical outcome at different time points following STEMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants who entered treatment for methamphetamine use disorder
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Levels of Conjugated Bilirubin (BMG, BDG, UCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Severe Bleeding Episodes Who Demonstrated Response to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence or Absence of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Presence or Absence of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of tissue needed for CESB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of NCD screening offered in communities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to follow-up advice
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Uptake of health education (health promotion, awareness of risk factors)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Structured Clinical Interview for DSM-5 (SCID-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Eating Disorder Fear Inventory (EFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Eating Disorder Examination Questionnaire 6.0 (EDE-Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time from end of sedation to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (%)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events (number)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of adverse events (CTCAE v5.0 criteria)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cycles which obtained euploid blastocysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Concentration of AMO+MET and AZI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in repositioning of fractured segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of participants with DLT and Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced solid tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with Objective Response as determined by Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overhead flexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-leg balance hold duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poor neurological outcome (≥4 on modified Rankin scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160 and who Develop Neutralizing Antibodies to rHuPH20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival to Hospital Admission
Endpoint domain: Mortality/survival
Primary endpoint: Rhythm Change post defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood chemistry levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Grams of Vegetables Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural MRI brain volumetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of cardio-oncology consultation visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in skin microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in skin microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Work productivity of relatives
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Activity levels of relatives
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Tolerance to Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Static Two Point Discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Semmes-Weinstein Monofilament Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Baseline Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Parent-Reported Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of grade II-IV acute Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Social Anxiety and Avoidance Scale for Adolescents
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Generalized Anxiety Disorder - 7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful engraftment of hair follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of the DEMMI score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD4+ immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8+ immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+/CD8+ immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subject Drop Out Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Returned Number of Tablets
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: International Physical Activity Questionnaire (Short Form)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hemodynamic signal change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Successfully Screened in Participants who Enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Center for Epidemiologic Studies - Depression (CES-D) Questionnaires Completed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Biomolecular Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive Range of Motion of Shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Finger Joint Position Sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Manual ability classification system
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of eligible individuals who agree to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion of the one-month follow-up assessment survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of the three-month follow-up assessment survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants who remain active (in text-support condition only)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participant satisfaction with the intervention components
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to first supplemental dose of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity grade change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Propofol Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of AMT-260
Endpoint domain: Adverse events/effects
Primary endpoint: oncRNA test clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patient decisions made in line with evidence based best practice guidelines
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of Participants With Solicited Local and Systemic Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Any Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Study Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Any Medically Attended AEs (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in vaccine effectiveness of prophylactic HPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in long-term antibody responses to HPV vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: first attempt intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post tonsillectomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post tonsillectomy bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and intensity of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and intensity of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Swallowing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung defense reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Power of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Voice efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Velar efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients receiving pharmaceutical interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Partial pressure of arterial oxygen (pa02)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial pressure of carbon dioxide (pC02)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expression of colonic (NF)-κB proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effective rate at 6 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving for substance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Craving for food
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aspirin success in preeclampsia prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proinflammatory Blood Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-Inflammatory Blood Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HPV-related Oropharyngeal Cancer knowledge, perceptions, practices and barriers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sickle Cell Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Secretion rates of ACE-inhibitors into breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infrarenal abdominal aortic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in endoscopic assessment of mucosal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total Calories of Sugary Drinks Purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exudate absorption by IMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Exudate accumulation in the wound by IMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence and severity of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Passive dorsiflexion of ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in diagnosis of PPROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with technically successful completion of the ESG procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tumor progression rate detected by ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serum NSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Events Within 1 Month After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in time of Dim Light Melatonin Onset (DLMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success of H. pylori treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in parental depression, anxiety and stress score over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measure of NICU parent stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measure of parent-child bonding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of radiation-induced mucosal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Limb based patency at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: POLE mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: microsatellite instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Capillary Wedge Pressure (PCWP) at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total number of patients who survive
Endpoint domain: Mortality/survival
Primary endpoint: Changes in exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in New York Heart Association (NYHA) functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemoglobin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bleeding quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Goodman Baron's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of TDP-43 aggregates in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression profile under Nrf-2 control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal gross income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Employment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Long-term sickness absence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of near-infrared fluorescent imaging
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of near-infrared fluorescent imaging
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of near-infrared fluorescent imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-confidence of mothers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hip flexion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical lordosis angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lumbar lordosis angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Grade 2 or higher acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: peri papillary capillary density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frontal Alpha Asymmetry (FAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychiatric symptom severity for a history of Major Depressive Disorder (MDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in overall functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major adverse events (Mortality and rehospitalization)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events (AE) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Safety laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstetric Quality of Recovery 11 score (ObsQoR-11)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to cessation of vasopressor support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physiological lens tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite score of recurrent venous thromboembolism and clinically relevant bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Unaltered pathological T-stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amplitude of gluteus maximus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Amplitude of latissimus dorsi muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anterior translation of humeral head
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 90 day all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incorporation of IRT for CVD into routine primary care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lactate clearance greater than 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes